Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China
Saved in:
Main Authors: | Xingxian Luo (Author), Yang Xu (Author), Xin Du (Author), Xufeng Lv (Author), Si Chen (Author), Yue Yang (Author), Lin Huang (Author), Xiaohong Zhang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
by: Shunsuke Matsushita, et al.
Published: (2021) -
Regulatory lessons from China's COVID-19 vaccines development and approval policies
by: Jingshu Yang, et al.
Published: (2022) -
A comparative analysis of vaccine lists, prices, and candidates, and the national immunization program between China and the United States
by: Xingxian Luo, et al.
Published: (2024) -
Healthy cities initiative in China: Progress, challenges, and the way forward
by: Yuqi Bai, et al.
Published: (2022) -
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
by: Ebru Demirci, et al.
Published: (2023)